RELMADA THERAPEUTICS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-12-31 was $0.00.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $246.75K.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-09-30 was $286.18K, a 448.69% increase year-over-year.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for the quarter ending 2022-06-30 was $352.74K.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $246.75K.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2022 was $703.72K, a 5.28% increase from fiscal 2021.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2021 was $668.43K, a 9.12% decline from fiscal 2020.
- RELMADA THERAPEUTICS, INC. stock issued during period, value, stock options exercised for fiscal 2020 was $735.51K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $246.75K 10-K · filed 2026-03-19 |
| 2024-03-31 | $246.75K 10-Q · filed 2025-11-13 | |
| 2022-12-31 | $703.72K 10-K · filed 2024-03-19 | |
| 2022-09-30 | $286.18K 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $352.74K 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $64.80K 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $668.43K 10-K · filed 2023-03-23 | |
| 2021-09-30 | $52.16K 10-Q · filed 2021-11-12 | |
| 2020-12-31 | $735.51K 10-K · filed 2022-03-25 | |
| 2020-09-30 | $105.88K 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $457.62K 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $73.02K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |